Wall Street Sees 84% Upside in Hims & Hers (HIMS) Despite This Month's 48% Selloff

Wall Street Sees 84% Upside in Hims & Hers (HIMS) Despite This Month's 48% Selloff

Quick Read Hims & Hers (HIMS) fell 47.96% after FDA crackdown on compounded weight-loss drugs and Novo Nordisk patent lawsuit forced cancellation of Wegovy alternative. Hims posted Q3 revenue of $599M with 49% growth and 2.5M subscribers. Analysts see $29.96 target representing 84% upside. Hims generated $148.7M operating cash flow in Q3. CFO bought shares at $5.01 and $11.53 during the February selloff. You can earn up to $1,500 in cash bon…